Incidence of interstitial pneumonitis in non-Hodgkin ’s lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab

This study is aimed to investigate the incidence of interstitial pneumonitis in non-Hodgkin ’s lymphoma (NHL) patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. Lymphoma patients were retrospectively reviewed, and eligible patients were included in this study. According to the chemotherapy regimens, patients were classified in four groups: combinati on of vincristine, cyclophosphamide, doxorubicin, and prednisone (CHOP group) with rituximab (RCHOP group) and combination of vincristine, cyclophosphamide, pegylated liposomal doxorubicin and prednisone (CDOP group) with rituximab (RCDOP group). Incidence and severity of interstitial pneumonitis we re compared among the four groups. Among 757 patients reviewed, 207 patients were included in final analysis. Thirteen patients developed chemotherapy-induced interstitial pneumonitis, and the mean cycle of chemotherapy before the onset of pneumonitis was 4. Incidence rates of pneumonitis were 0, 1. 8, 17.4, and 21.1% in CHOP, RCHOP, CDOP, and RCDOP groups, respectively (p <  0.001). The mean grades of pneumonitis were 0, 2, 2.5, and 3 in four groups, respectively (p <  0.001). After adjustment of confounders, chemotherapy regimens (OR 3.491, 95% CI 1.527–7.981,p = 0.003) and neutropenia in previous cycles (OR 2.186, 95% CI 1.281–3.731,p = 0.004) were independently associated with the incidence of pneumonitis. Interstitial pneumonitis should be highlighted in NHL patients who r...
Source: Annals of Hematology - Category: Hematology Source Type: research